Differential antifungal activity of isomeric forms of nystatin.
When nystatin is placed in RPMI and other biological fluids, there is loss of pure nystatin, with the development of two distinguishable chromatographic peaks, 1 and 2. Peak 1 appears identical to commercially prepared nystatin. By nuclear magnetic resonance (NMR) and mass spectral analysis, peak 2 appears to be an isomer of peak 1. The isomers are quantitatively and fully interconvertible. Formation of peak 2 is accelerated at a pH of >7.0 and ultimately reaches a near 55:45 (peak 1/peak 2 ratio) mixture. We sought to determine the relative activities of peaks 1 and 2 against Candida spp. Peak 2 consistently showed higher MICs when it was the predominant form during the experiment. Time-kill analyses showed that peak 2 required > or =8 x the concentration of peak 1 to produce a modest and delayed killing effect, which was never of the same magnitude as that produced by peak 1. In both types of assays, the activity of peak 2 corresponded with intra-assay formation of peak 1. Both MIC measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against Candida spp. Peak 2 may serve as a reservoir for peak 1.
Ostrosky-Zeichner
L
L
Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine, University of Texas Houston Medical School, 6431 Fannin, Houston, TX 77030, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu
Bazemore
S
S
Paetznick
V L
VL
Rodriguez
J R
JR
Chen
E
E
Wallace
T
T
Cossum
P
P
Rex
J H
JH
D000935:Antifungal Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D002845:Chromatography; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000302:isolation & purification / Q000494:pharmacology*; D020033:Protein Isoforms / Q000494:pharmacology; D013997:Time Factors
D000935:Antifungal Agents; D020033:Protein Isoforms; D009761:Nystatin